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Cardiotrophin 1 (CT-1) is a member of the interleukin 6 superfamily that interacts with the heterodimer consti-
tuted by the glycoprotein 130 and the leukemia inhibitory fac-
tor receptor-β.1 Our group has described that CT-1 induces cell 
proliferation, hypertrophy, and secretion of extracellular matrix 
proteins in aortic vascular smooth muscle cells (VSMCs) in 
vitro2 and in vivo,3 suggesting a role for CT-1 in arterial fibrosis 
and stiffness, which both are features of aging. Furthermore, 
elevated plasma concentrations of CT-1 have been reported in 
patients with a variety of diseases, including hypertension,4 
heart failure,5 uns table angina,6 myocardial infarction,7 and 
aortic stenosis,8 indicating that this cytokine may contribute to 
the development of cardiovascular pathologies associated with 
aging.
Arterial walls stiffen with age. The arterial wall is a com-
plex tissue composed of different cell types subject to struc-
tural and functional modifications. Age-associated changes 
in blood vessels include the increase in the inflammatory 
response, the cell loss, the inability to repair DNA damage, 
the oncogenic activation, and the regulation of telomere-
telomerase complex.9–11 A number of age-associated struc-
tural, functional, and molecular changes occur in the arterial 
system. Aging is associated with thickening and dilatation 
of large arteries, extracellular matrix accumulation, calcium 
deposits, increased vascular stiffness, and endothelial dys-
function.12,13 It has been suggested that these alterations are 
attributable to age-related functional changes in vascular 
cells.12 The age-associated arterial inflammatory phenotype 
includes increased expression of monocyte chemoattractant 
protein 1, intercellular adhesion molecule 1, matrix metal-
loproteinase-2 activity, or transforming growth factor-β1 
expression.14,15
Here, we investigated whether the absence of CT-1 in mice 
confers protection from arterial stiffness and fibrosis with 
an impact on vascular senescence and overall mortality. To 
understand the effects of CT-1 in arterial stiffness associated 
with aging, we studied a cohort of senescent (29-month-
old) CT-1–null mice and their wild-type (WT) littermates. 
Abstract—Cardiotrophin 1 (CT-1), an interleukin 6 family member, promotes fibrosis and arterial stiffness. We hypothesized 
that the absence of CT-1 influences arterial fibrosis and stiffness, senescence, and life span. In senescent 29-month-
old mice, vascular function was analyzed by echotracking device. Arterial histomorphology, senescence, metabolic, 
inflammatory, and oxidative stress parameters were measured by immunohistochemistry, reverse transcription polymerase 
chain reaction, Western blot, and ELISA. Survival rate of wild-type and CT-1–null mice was studied. Vascular smooth 
muscle cells were treated with CT-1 (10−9 mol/L) for 15 days to analyze senescence. The wall stress-incremental elastic 
modulus curve of old CT-1–null mice was shifted rightward as compared with wild-type mice, indicating decreased 
arterial stiffness. Media thickness and wall fibrosis were lower in CT-1–null mice. CT-1–null mice showed decreased 
levels of inflammatory, apoptotic, and senescence pathways, whereas telomere-linked proteins, DNA repair proteins, 
and antioxidant enzyme activities were increased. CT-1–null mice displayed a 5-month increased median longevity 
compared with wild-type mice. In vascular smooth muscle cells, chronic CT-1 stimulation upregulated apoptotic and 
senescence markers and downregulated telomere-linked proteins. The absence of CT-1 is associated with decreased 
arterial fibrosis, stiffness, and senescence and increased longevity in mice likely through downregulating apoptotic, 
senescence, and inflammatory pathways. CT-1 may be a major regulator of arterial stiffness with a major impact on the 
aging process.  (Hypertension. 2013;61:120-129.) 
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Vascular function, inflammation, senescence, telomere-linked 
proteins, DNA repair proteins, antioxidant enzyme activities, 
and mortality were measured. Moreover, primary VSMCs 
were used to further characterize the effect of CT-1 chronic 
treatment on senescence in vitro.
Methods
Animals and Assessment of Life Span
The investigation was performed in accordance with the National 
Institutes of Health Guide for Care and Use of Laboratory Animals. 
WT and CT-1–null mice backcrossed into a C57BL6 background 
were obtained from D. Pennica (Genentech). Animals were housed 
in a constant temperature room, with a 12-hour dark/12-hour light 
cycle, and allowed free access to standard diet and water. Only male 
littermates were used. A number of mice were euthanized at the age 
of 22 (4 WT and 7 CT-1–null), 29 (14 WT and 13 CT-1–null), and 
36 months (4 CT-1–null). For functional, histological, molecular, and 
biochemical studies (heart, aorta, and blood), only 29-month-old WT 
(n=14) and CT-1–null (n=13) mice were used.
Biochemical Measurements
Blood glucose levels were measured using a Glucometer Elite 
(Bayer) at month 29, after overnight fasting. Plasma insulin, leptin, 
and resistin levels were determined with ELISAs (Linco Research). 
Plasma CT-1, C-reactive protein, plasminogen activator inhibitor 
1, tumor necrosis factor-α, and interleukin 4 levels were measured 
by ELISA (R&D Systems). The activity of superoxide dismutase 
and glutathione in plasma was quantified by ELISA (Cayman 
Chemical).
In Vivo Carotid Mechanical Properties
We recorded intra-arterial diameter of the carotid artery and blood 
pressure (BP) in isoflurane-anesthetized old mice using an ultra-
sonic echotracking device (NIUS-01, Asulab SA), as described 
previously.16
Morphological and Histological Evaluation
Histological determinations in vascular tissue were performed in 
5-μm–thick sections stained with hematoxylin for carotid mor-
phometry, with orcein for elastin content and with Sirius red for 
collagen content, as reported previously.17 Media thickness has been 
measured in triplicate in a minimum of 10 WT and 10 CT-1–null 
mice. For the identification of DNA fragmentation, terminal deoxy-
nucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) 
staining was performed following the manufacturer’s instructions 
(Roche).
Reverse Transcription and Real-Time Polymerase 
Chain Reaction
Total RNA extraction was performed using a nucleic acid purifica-
tion lysis solution (Applied Biosystems) and the semiautomated ABI 
PRISM 6100 Nucleic Acid PrepStation system (Applied Biosystems). 
Real-time polymerase chain reaction was performed with an ABI 
PRISM 7000 Sequence Detection System by using specific TaqMan 
MGB fluorescent probes (Applied Biosystems). Constitutive 18S 
ribosomal RNA was used as endogenous control.
Western Blot
Aortas and VSMCs were homogenized in lysis buffer (Roche). 
Protein concentration was determined by the Lowry method (Bio-
Rad). Proteins (30 μg) were separated by SDS polyacrylamide 
gel electrophoresis and transferred to nitrocellulose membranes 
(Amersham Biosciences). Blots were visualized using an ECL-Plus 
chemiluminiscence detection system (Amersham Biosciences). 
Bands were quantified by densitometry and normalized by β-actin 
values.
Cell Cultures
Primary rat aortic VSMCs were isolated by using standard enzymatic 
dissociation techniques.2 Cells were plated and grown in DMEM 
(Invitrogen) supplemented with 5% FBS and cultured at 37°C in air 
Table. Metabolic, Inflammatory, Oxidative Stress, and 
Vascular Parameters in 29-Month-Old WT and CT-1–Null Mice
Parameter WT CT-1-Null
General parameters
 N 14 13
 BW, g 33±0.4 37±1.4*
 HW, g 0.206±0.01 0.200±0.01
 HW/BW, mg/g 6.0±0.3 5.4±0.2
 KW, g 0.298±0.01 0.299±0.01
 KW/BW, mg/g 8.7±0.2 8.2±0.3
 SBP, mm Hg 97±4 107±3
 DBP, mm Hg 68±2 80±2†
 MBP, mm Hg 78±3 89±2†
 PP, mm Hg 29±3 27±2
 HR, bpm 427±15 484±15†
Vascular parameters (at MBP)
 N 12 12
 Carotid diameter, mm 0.52±0.03 0.57±0.02
 Carotid compliance 1.8±0.2 2.2±0.1
 Distensibility, 10−3/mm Hg 8.6±0.9 8.7±0.7
 Incremental elastic modulus, kPa 454±91 651±150*
 Wall stress, kPa 154±25 255±27*
 Carotid MCSA, µm2 10−3 31.4±1.2 25.2±1.8*
 Carotid media thickness, µm 24.5±1.6 16.4±1.3*
Histological aortic parameters
 Aortic MCSA, µm2 10−3 154±11 122±12*
 Aortic media thickness, µm 73±4.1 58±3.3*
 Ki-67 positive nuclei, % <0.01 <0.01
Oxidative stress parameters
 SOD, U/mL 0.53±0.07 1.08±0.07*
 Glutathione, µg/mL 2.3±0.08 3.5±0.3†
Inflammatory parameters
 CRP, pg/mL 3392±490 1770±114*
 PAI-1, pg/mL 68±9 25±3*
 TNF-α, pg/mL 253±48 124±31*
 IL-4, pg/mL 62±12 63±21
Metabolic parameters
 Fasting blood glucose, mg/dL 137±8 137±14
 Resistin, ng/mL 6.2±0.8 7.4±0.9
 Adiponectin, ng/mL 4.7±0.4 6.1±0.4†
 Leptin, ng/mL 4.5±0.1 2.2±0.4†
WT indicates wild type; CT-1, cardiotrophin 1; BW, body weight; HW, heart 
weight; KW, kidney weight; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; MBP, mean blood pressure; PP, pulse pressure; HR, heart rate; MCSA, 
media cross-sectional area of the carotid artery; SOD, superoxide dismutase; 
CRP, C-reactive protein; PAI-1, plasminogen activator inhibitor 1; TNF-α, tumor 
necrosis factor alpha; IL-4, interleukin 4.
*P<0.01 vs WT.
†P<0.05 vs WT.
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containing 5% CO
2
. Cells were used at passages 2 to 6. Before treat-
ments, cells were serum starved for 12 hours. In all of the experi-
ments, to expose to CT-1 (10−9 mol/L) for the indicated times, the 
conditioned medium was aspirated, and we added quickly the fresh 
culture medium without FBS every 24 hours.
Senescence-Associated β-Galactosidase Staining
Senescence-associated β-galactosidase (SA-β-gal) activity was 
detected as a biomarker for cellular senescence. Cell that were 50% 
to 60% confluent and quiescent cultured on Lab Tek chambered 
coverglass (Nunc) were exposed to CT-1 (10−9 mol/L) for 1, 7, 
and 15 days. SA-β-gal staining was performed using a Senescence 
Detection kit (Sigma). The number of total and SA-β-gal-positive 
cells was counted in 10 randomly chosen fields per group at ×20 
magnification.
Statistical Analysis
Results are presented as mean±SE, computed from the average 
measurements obtained from each group of animals or cells. The 
time occurrence of death (months) was assessed by Kaplan-Meier 
cumulative survival functions. Survival distribution between the 2 
groups of mice was compared using the log-rank test. Normal dis-
tribution of data was checked using the Shapiro-Wilk test. A Levene 
statistic test was performed to check the homogeneity of variances. 
Differences among more than 2 experimental conditions were 
tested by the ANOVA 1-way test, followed by the Scheffé test to 
analyze differences between groups. The unpaired Student t test or 
the Mann Whitney U test was used to assess statistical differences 
between 2 experimental conditions. P values <0.05 were considered 
significant.
Results
Absence of CT-1 Is Associated With Decreased 
Arterial Stiffness
The heart weight, the heart weight:body weight ratio, the kid-
ney weight, and the kidney weight:body weight ratio were 
comparable between CT-1–null and WT mice. BP and heart 
rate were slightly increased in mice lacking CT-1 (Table).
There were no changes in carotid diameter, compliance, 
and distensibility calculated at mean BP. By contrast, incre-
ment elastic modulus (E
inc
) and wall stress (WS) values were 
higher (P<0.01) in CT-1–null mice when compared with WT 
animals. The diameter-arterial pressure curve in CT-1–null 
mice tended to be shifted upward when compared with the 
curve for WT animals (Figure 1A). The distensibility-arte-
rial pressure curve in CT-1–null group was shifted upward 
(P<0.05) compared with the WT group, indicating that mice 
lacking CT-1 presented higher distensibility for a given BP 
(Figure 1B). As for the E
inc
-WS curves, they were shifted to 
the right (P<0.05), toward higher values of WS (in compari-
son with WT mice) (Figure 1C). The comparison between WT 
and CT-1–null mice curves was made by calculating the mean 





In CT-1–null mice, MWS was increased (P<0.01), indicat-
ing a decrease in stiffness (Figure 1D). Thus, the absence of 
CT-1 was associated with increased arterial distensibility and 
decreased stiffness of the arterial wall material.
Absence of CT-1 Is Associated With Decreased 
Arterial Fibrosis
As can be seen in the Table, carotid media cross-sectional 
area and media thickness were lower in CT-1–null animals 
when compared with WT mice (20% and 33%, respectively; 
representative photographs are shown in Figure 1E). 
Moreover, CT-1–null mice had a lower carotid collagen 
density (40%; P<0.01) than WT mice, but the absence of CT-1 
did not affect elastin amounts (Figure 1E). In accordance with 
these observations, the aortic media cross-sectional area and 
the aortic media thickness were also diminished in CT-1–null 
mice when compared with WT. These differences were not 
because of VSMC proliferation, because the percentage of 
ki-67-positive nuclei was similar in WT and CT-1–null mice 
(Table). The aortic expression of α-1-procollagen mRNA was 
reduced (40%; P<0.01), as was the expression of collagen type 
I (60%; P<0.01) and collagen type III (35%; P<0.01) in CT-1–
null mice compared with WT mice (Figure 1F). Fibronectin 
mRNA and protein expression were also decreased in aorta 
from mice lacking CT-1 compared with WT mice (30% and 
45%; P<0.01, respectively; Figure 1F). Furthermore, matrix 
metalloproteinase-2, -9, and -13 activities were reduced (55%, 
P<0.05; 40%, P<0.05; and 70%, P<0.01, respectively) in 
aorta from CT-1–null mice when compared with WT animals 
(Figure 1G).
Absence of CT-1 Is Associated With Decreased 
Arterial Senescence and Apoptosis
To test whether a decrease in vascular apoptosis and 
senescence could be associated with the decreased arterial 
stiffness of CT-1–null mice, these processes were evaluated 
in old WT and CT-1–null mice. As shown in Figure 2A, 
aortic Bax expression was reduced (44%; P<0.01) in mice 
lacking CT-1, whereas Bcl-2 expression was increased (64%; 
P<0.01). Moreover, old CT-1–null mice exhibited decreased 
cleaved caspase-3 and cleaved poly (ADP-ribose) polymerase 
(47% and 40%, respectively; P<0.05), when compared 
with WT mice. These results were confirmed by TUNEL 
and poly (ADP-ribose) polymerase staining (Figure 2B), 
showing low apoptosis in aorta from mice lacking CT-1. This 
decreased aortic apoptosis in CT-1–null mice, but not in WT 
animals, was accompanied by a decrease in the expression 
of senescence markers. As shown in Figure 2C, vascular p53 
was diminished in mice lacking CT-1 (38%; P<0.05). The 
expression of Mdm2, the principal cellular antagonist of p53, 
was enhanced (88%; P<0.01) in old CT-1–null animals when 
compared with WT. The expression of the others senescence 
markers, p21 and p16, was also decreased in aortas from 
CT-1–null mice when compared with WT (44% and 45%, 
P<0.05, respectively).
To analyze whether the absence of CT-1 could alter the 
proteins that protect telomeres, vascular expression of DNA-
dependent protein kinase catalytic subunit, ku86 (the regu-
latory component of the DNA-associated protein kinase), 
TRF-2 (telomeric repeat-binding factor-2 that regulate 
telomerase by protecting the chromosome ends), and TERT 
(catalytic subunit of the enzyme telomerase) was quantified. 
As shown in Figure 2D, the expression of all of these pro-
teins was augmented in aorta from CT-1–null mice when 
compared with WT (90%, 300%, 300%, and 450%, P<0.01, 
respectively).
Figure 2E shows vascular expression of nuclear factor-
κB (NFκB) pathway, which regulates cellular responses and 
is the first responder to harmful cellular stimuli, in WT and 
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CT-1–null mice. Mice lacking CT-1 presented decreased vas-
cular phosphorylation of IKK (Iκb kinase) α/β (46%, P<0.01), 
IκBα (30%, P<0.05), and NFκB (47%, P<0.01) when com-
pared with WT mice.
Absence of CT-1 Is Associated With Increased 
Antioxidant and Decreased Inflammatory State
The analysis of the antioxidant system in 29-month-old CT-1–
null mice showed an increased superoxide dismutase activity 
(200%, P<0.01) and glutathione activity (152%, P<0.05) 
when compared with age-matched WT controls (Table). 
Furthermore, mice lacking CT-1 presented decreased levels of 
plasma pro-inflammatory molecules C-reactive protein (48%, 
p<0.01), plasminogen activator inhibitor 1 (63%, P<0.01), 
and tumor necrosis factor-α (51%, P<0.01) and similar levels 
of the anti-inflammatory cytokine IL-4 when compared with 
WT mice (Table). In parallel, we investigated metabolic fea-
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Figure 1. In vivo carotid mechanical properties and vascular morphology and composition in wild-type (WT) and cardiotrophin 1  
(CT-1)–null mice. A, The diameter-arterial pressure curve of the CT-1–null mice group (n=12) was shifted upward vs WT (n=12). B, For 
a given level of arterial pressure, there was a significant upward shift of the distensibility-pressure curve in CT-1–null mice. C, The wall 
stress (WS)–increment elastic modulus (Einc) curve of CT-1–null mice was significantly shifted to the right vs controls. D, Mean wall stress 
(MWS) within the 350- to 1000-kPa range of Einc (MWS 250-800) was increased in CT-1–null mice. E, Carotid artery from CT-1–null mice 
exhibited decreased media cross-sectional area and collagen content whereas elastin levels were not modified when compared with 
WT. F, CT-1–null mice presented decreased aortic α-1-procollagen, collagen type I, collagen type III, fibronectin mRNA, and fibronectin 
protein expression. G, Aortic matrix metalloproteinase-2 (MMP-2), -9 and -13 activities were diminished in CT-1–null mice when 
compared with WT. The images are representative of 3 independent experiments and histograms with bars represent the mean±SE of 
≤10 WT and 10 CT-1–null mice. *P<0.01 vs WT; †P<0.05 vs WT.
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Figure 2. Apoptotic, senescence markers, telomere-related proteins, and nuclear factor-κB (NFκB) pathway activity in aorta from wild-
type (WT) and cardiotrophin 1 (CT-1)–null mice. A, The apoptotic markers Bax, Bcl-2, caspase-3, and poly (ADP-ribose) polymerase 
(PARP) were evaluated in the aorta from old WT and CT-1–null mice. Old CT-1–null mice showed decreased vascular apoptosis when 
compared with WT. B, Representative microphotographs of TUNEL (terminal deoxynucleotidyltransferase-mediated dUTP nick end 
labeling) and PARP staining in aorta from WT and CT-1–null mice showed decreased apoptosis in CT-1–null mice when compared 
with WT. C, The senescence markers p53, Mdm2, p21, and p16 were evaluated in the aorta from old WT and CT-1–null mice. Old CT-
1–null mice presented diminished vascular senescence when compared with WT. D, The telomere integrity markers DNA-dependent 
protein kinase catalytic subunit (DNA-PKcs), ku86, TRF-2 (telomeric repeat-binding factor-2), and TERT (catalytic subunit of the enzyme 
telomerase) were evaluated in the aorta from old WT and CT-1–null mice. Old CT-1–null mice showed increased telomere-related proteins 
when compared with WT. E, Old CT-1–null mice presented diminished vascular NFκB pathway activity when compared with WT. The 
images are representative of 3 independent experiments and histograms with bars represent the mean±SE of ≤10 WT and 10 CT-1–null 
mice. *P<0.01 vs WT; †P<0.05 vs WT.
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of 29-month-old mice revealed that CT-1–null mice presented 
an increase in body weight (12%, P<0.01) when compared 
with their littermates WT. Concentrations of fasting blood 
glucose and resistin did not significantly differ in CT and 
CT-1–null mice, whereas adiponectin levels were increased 
(130%, P<0.05) and leptin concentration was decreased (51%, 
P<0.05) in CT-1–null mice when compared with WT (Table).
Absence of CT-1 Is Associated With Increased Life 
Span in Mice
Among the 42 mice of the study, 18 (7 WT and 11 CT-1-null) 
were euthanized around 29 months for histological assess-
ment: they were coded as censored at the time of euthanize 
in the survival analysis. The 4 surviving CT-1–null mice 
were euthanized at the end of the study (36 months). Twenty 
mice (11 WT and 9 CT-1-null) died spontaneously during 
follow-up. CT-1–null mice substantially outlived their WT 
littermates, with median survival time of 33 and 28 months, 
respectively (P=0.007) (Figure 3). There was no difference in 
life span between 1 and 21 months.
CT-1 Induces Apoptosis and Premature Senescence 
In Vitro in VSMCs
To determine whether CT-1 induced vascular apoptosis and 
senescence in vitro, VSMCs were treated with CT-1 for 1, 7, 
and 15 days. The percentage of SA-β-galactosidase-positive 
VSMC was significantly increased (P<0.01) by CT-1 in a 
time-dependent manner, starting 7 days after CT-1 stimulation 
(Figure 4A). CT-1 treatment also increased time-dependently 
(P<0.01) VSMC apoptosis assessed by Bax/Bcl-2 ratio, cas-
pase-3 cleavage and Poly (ADP-ribose) polymerase cleavage 
time-dependently (Figure 4B), and the senescence mark-
ers p53, p21, and p16, without modifying Mdm2 expression 
(Figure 4C and 4D).
CT-1 Decreases Telomere Integrity and Telomerase 
Activity and Increases NFκB Pathway Activity In 
Vitro in VSMCs
The effects of CT-1 on the expression of proteins that pro-
tect telomeres were analyzed. As shown in Figure 5A and 
5B, VSMCs treated with CT-1 for 15 days exhibited reduced 
levels of DNA-dependent protein kinase catalytic subunit, 
ku86, and TRF-2 expression (P<0.05). However, in both 15 
days control and CT-1–treated cells, an increase (P<0.05) in 
TERT expression was found (Figure 5B). Moreover, CT-1 
treatment increased (P<0.05) phosphorylation of IκBα and 
NFκB without modifying IKK (Iκb kinase) α/β activation 
in VSMCs.
Discussion
In the present study, for the first time, we report that the 
absence of CT-1 translated into a marked reduction in arte-
rial stiffness associated with aging. Mice lacking CT-1 
developed less vascular fibrosis with lower deposition of 
extracellular matrix proteins, mainly collagen type I and 
fibronectin. This occurred despite slightly higher mean 
BP, however still in the reference range. This was associ-
ated with a lower inflammation and oxidative stress and a 
reduced senescence, resulting in a prolongation of the mice 
life span. Such phenomena are in line with our in vitro 
results showing that CT-1 treatment prematurely provoked 
cellular senescence in VSMCs.
Age-associated changes in blood vessels include a 
decrease in compliance, an increase in arterial stiffness and 
arterial wall thickening as a result of increased vascular cal-
cifications, increased collagen content and cross-linking, and 
decreased elastin content.16,18 Thus, several clinical studies 
have shown a strong association between arterial stiffness 
and cardiovascular morbidity and mortality.19,20 In this regard, 
it has been described that CT-1 stimulated bone formation 
in vitro and in vivo21 and enhanced collagen synthesis and 
matrix metalloproteinase activities in VSMCs without modi-
fying elastin levels,2 suggesting a role for the cytokine in 
vascular calcifications and arterial stiffness. According to 
these findings, aged mice lacking CT-1 presented decreased 
arterial stiffness and media thickness accompanied by dimin-
ished collagen and fibronectin content and decreased matrix 
metalloproteinase activities. In addition to structural changes, 
arterial stiffness is strongly affected by VSMC tone, which 
can be modified by mechanostimulation itself and by para-
crine mediators, such as oxidative stress.22 Oxidative stress is 
a major contributor to aging.23 The observation of increased 
superoxide dismutase and glutathione activities in old mice 
lacking CT-1 compared with WT mice suggests that CT-1 
may affect organ senescence though induction of oxida-
tive stress. In this respect, it has been evidenced that CT-1 
increased reactive oxygen species in cardiomyocytes, regu-
lating Jak/Stat and NFκB signaling pathway,24 raising the 
possibility that CT-1 exert its biological effects via an eleva-
tion of oxidative stress. In the present study, on stimulation 
of VSMCs with CT-1, Stat-3 phosphorylation, and NFκB sig-
naling pathway activity increased. According to this, NFκB 
signaling pathway activity was not modified with aging in 
mice lacking CT-1, whereas the activity augmented with 
aging in WT mice. Thus, the absence of CT-1 protected mice 
from the deleterious process of oxidative stress maybe by 
downregulating NFκB signaling pathway activity.
Cellular senescence is characterized by biochemical events 
that occur within the cell leading to growth arrest and loss 




















Mice left at risk:
KO           24                  15                  13                   9                     5                    4
WT           18                  12                   8                    0                     0                    0
Figure 3. Increased life span of cardiotrophin 1 (CT-1)–null mice. 
Kaplan-Meier analysis of survival in male CT-1–null mice and 
wild-type (WT) littermates is shown. The life span of the CT-1–null 
mice was 5 months longer than controls. KO indicates knockout.
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1         7       15       1        7      15
Control                 CT-1
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Control                 CT-1
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1         7       15       1          7       15
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Control                   CT-1
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Figure 4. Apoptotic and senescence markers in vascular smooth muscle cells (VSMCs) treated with cardiotrophin 1 (CT-1). A, CT-1 
treatment enhanced SA-β-Gal activity. B, The apoptotic markers Bax, Bcl-2, caspase-3, and poly (ADP-ribose) polymerase (PARP) were 
increased by chronic CT-1 treatment. C and D, CT-1 enhanced the expression of the senescence markers p53, Mdm2, p21, and p16. The 
images are representative of 3 independent experiments and histograms with bars represent the mean±SE of ≤3 separate experiments. 
*P<0.05 vs control 1 day; $P<0.05 vs control 15 days.
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Control                  CT-1
1         7       15       1          7       15
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Control                  CT-1
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Control              CT-1
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Control              CT-1
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Control              CT-1
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Figure 5.  Telomere-related proteins and nuclear factor-κB (NFκB) pathway activity in vascular smooth muscle cells (VSMCs) treated 
with cardiotrophin 1 (CT-1). A and B, The telomere integrity markers DNA-PKcs, ku86, TRF-2 (telomeric repeat-binding factor-2), and 
TERT (catalytic subunit of the enzyme telomerase) were evaluated in VSMCs treated with CT-1. Cells treated chronically with CT-1 
presented decreased telomere-related proteins. C, NFκB pathway activity was enhanced on treatment with CT-1. D, CT-1 decreased 
Akt phosphorylation and increased Stat-3 phosphorylation in VSMCs. The images are representative of 3 independent experiments and 
histograms with bars represent the mean±SE of ≤3 separate experiments. *P<0.05 vs control 1 day; $P<0.05 vs control 15 days. at UNIVERSIDAD DE NAVARRA on May 30, 2014http://hyper.ahajournals.org/Downloaded from 
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divide, their ability to synthesize proteins is reduced, and 
the DNA repair system is attenuated.26 CT-1–null mice did 
not exhibit differences in VSMC proliferation but presented 
reduced cardiovascular apoptosis and senescence than WT 
mice. Moreover, the expression of proteins implicated in 
DNA repair and telomere integrity decreased or remained 
constant with age in WT but increased in CT-1–null mice. 
All these data point at the protective effect of the absence 
of CT-1.
Another group has also looked at cohorts of WT and 
CT-1–null mice27 and found opposite trends regarding 
differences in leptin concentrations between the groups 
(12-month-old CT-1–null mice presented increased body 
weight and leptin levels). One potential explanation for the 
difference is that they studied a younger cohort (12-month-
old) of mice, because our result in old mice showed a more 
modest increase in body weight accompanied by decreased 
leptin and increased adiponectin levels, suggesting that aging 
CT-1–null mice did not exhibit features of metabolic syn-
drome. Moreover, although BP values in CT-1–null mice 
were slightly increased, they were in the reference ranges. 
In addition, we and others have previously published that 
chronic CT-1 treatment could exert harmful effects at the car-
diovascular and metabolic levels. Thus, CT-1 impairs myo-
cardial contractility,28 induces myocardial remodeling1,17 and 
inflammation,29 and induces the development of insulin resis-
tance in vitro.30 The potential detrimental metabolic actions 
of CT-1 are supported by studies performed in patients with 
the metabolic syndrome in which an excess of this cytokine at 
the adipose tissue level and in the circulation were reported.31 
Furthermore, circulating CT-1 was associated with glucose 
levels in these patients.31 These data should be considered 
together and more complex and integrative specific analyses 
should be performed to better understand the role of CT-1 
treatment in metabolic disturbances.
Perspectives
Our findings have provided evidence that in the absence of 
CT-1 arterial stiffness is reduced in association with consistent 
patterns of diminished apoptosis, senescence, inflammation, 
and oxidative stress, potentially contributing to increased lon-
gevity. We thus suggest that CT-1 emerges as a target candi-
date to interfere with arterial stiffness associated to the aging 
process.
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What Is New?
•	 The absence of cardiotrophin 1 (CT-1) is associated with reduced arterial 
fibrosis and stiffness and delayed arterial senescence. Thus, CT-1 may be a 
major regulator of arterial stiffness with a major impact on the aging process.
What Is Relevant?
•	 Our results are particularly original, because antistiffening strategies (beyond 
antihypertensive treatment) are not available so far and are therefore an impor-
tant unmet clinical need. CT-1 could be a new therapeutic target to decrease 
arterial stiffness associated with the aging process.
Summary
The absence of CT-1 is associated with decreased arterial fibro-
sis, stiffness, and senescence and increased longevity in mice 
likely through downregulating apoptotic, senescence, and inflam-
matory pathways. CT-1 may be a major regulator of arterial stiff-
ness with a major impact on the aging process.
Novelty and Significance
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